Core Insights - Fulcrum Therapeutics is presenting preclinical data for FTX-6274, an EED inhibitor, which shows potential for treating castration-resistant prostate cancer at the ESMO Congress 2025 [1][2] - The company is exploring strategic partnerships to advance FTX-6274 for oncology indications, given its focus on non-malignant hematologic diseases [2] Company Overview - Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecules aimed at improving the lives of patients with genetically defined rare diseases [3] - The company's lead clinical program is pociredir, designed to increase fetal hemoglobin expression for treating sickle cell disease [3] - Fulcrum employs proprietary technology to identify drug targets that can modulate gene expression to address the root causes of gene mis-expression [3]